Guidance

Levothyroxine: a review of clinical and quality considerations

MHRA review of levothyroxine products in response to concerns about potential inconsistencies of different products.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 7 January 2013

Documents

Levothyroxine tablet products: a review of clinical and quality considerations

PDF, 178 KB, 24 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The review started in January 2011 and MHRA reviewed medical and scientific literature to assess:

• whether there could be differences in the bioavailability (extent/rate of absorption) of levothyroxine between different tablet products and/or batches
• what clinical implications this may have
• whether additional controls were needed

Published 7 January 2013